• Arginetix Inc., of Baltimore, said it completed a $2.3 million initial financing, which was co-led by Quaker BioVentures and MedImmune Ventures. Other investors included Red Abbey Venture Partners, Maryland Health Care Product Development Corp. and Acidophil LLC. Arginetix will put funds toward its work on small-molecule inhibitors of arginase in the initial indications of pulmonary arterial hypertension and erectile dysfunction associated with diabetes.